Consumption of caffeinated beverages and kidney function decline in an elderly Mediterranean population with metabolic syndrome

• Main Authors: Andrés Díaz-López, Indira Paz-Graniel, Verónica Ruiz, Estefanía Toledo, Nerea Becerra-Tomás, Dolores Corella, Olga Castañer, J. Alfredo Martínez, Ángel M. Alonso-Gómez, Julia Wärnberg, Jesús Vioque, Dora Romaguera, José López-Miranda, Ramon Estruch, Francisco J. Tinahones, José Lapetra, Luís Serra-Majem, Aurora Bueno-Cavanillas, Josep A. Tur, Vicente Martín Sánchez, Xavier Pintó, Miguel Delgado-Rodríguez, Pilar Matía-Martín, Josep Vidal, Clotilde Vázquez, Lidia Daimiel, Tania Fernandez Villa, Emilio Ros, Sonia Eguaras, Nancy Babio, Jose V. Sorlí, Albert Goday, Itziar Abete, Lucas Tojal Sierra, Francisco Javier Barón-López, Laura Torres-Collado, Marga Morey, Antonio Garcia-Rios, Rosa Casas, María Rosa Bernal-López, José Manuel Santos-Lozano, Adela Navarro, Jose I. Gonzalez, María Dolores Zomeño, Maria Angeles Zulet, Jessica Vaquero Luna, Raul Ramallal, Montse Fitó, Jordi Salas-Salvadó
• Format: Article
• Language: English
• Published: Nature Publishing Group 2021-04-01
• Series: Scientific Reports
• Online Access: https://doi.org/10.1038/s41598-021-88028-7

Abstract It remains unclear whether caffeinated beverages could have deleterious renal effects in elderly population with underlying comorbid conditions. We investigated the associations between coffee, tea, or caffeine intake and 1-year changes in glomerular filtration rate (eGFR) in a large Spanish cohort of overweight/obese elderly with metabolic syndrome (MetS). This prospective analysis includes 5851 overweight/obese adults (55–75 years) with MetS from the PREDIMED-Plus study. We assessed coffee, tea, and caffeine consumption from a validated food-frequency questionnaire and creatinine-based eGFR using the Chronic Kidney Disease Epidemiology Collaboration equation. Multivariate-adjusted regression models were applied to test associations between baseline coffee, tea, or caffeine intake and 1-year eGFR changes. Caffeinated coffee (> 2 cups/day) and tea (at least 1 cup/day) drinkers had 0.88 and 0.93 mL/min/1.73 m2 greater eGFR decrease respectively, compared to those with less than 1 cup/day of coffee consumption or non-tea drinkers. Furthermore, caffeinated coffee consumption of > 2 cups/day was associated with 1.19-fold increased risk of rapid eGFR decline > 3 mL/min/1.73 m2 (95% CI 1.01–1.41). Similarly, individuals in the highest (median, 51.2 mg/day) tertile of caffeine intake had a 0.87 mL/min/1.73 m2 greater eGFR decrease. Decaffeinated coffee was not associated with eGFR changes. In conclusion, higher consumption of caffeinated coffee, tea, and caffeine was associated with a greater 1-year eGFR decline in overweight/obese adults with MetS.